Asian Clinical Trials, the contract research organization (CRO) division of Suven Life Sciences, has a new regional office in Raleigh, North Carolina, headed by Hameed Allaudeen, VP of clinical research and regulatory affairs and supported by Deborah Smith, executive director of business development. Allaudeen has over twenty years of drug discovery and development experience in both academia and industry. Smith has over fifteen years of professional experience within the pharmaceutical-related industry.

LAB Research announced that it will host an exhibitor’s seminar titled “Study Design in Safety Pharmacology: Emerging Trends in Drug Development” at the upcoming 2008 Safety Pharmacology Society Meeting in Madison, WI. The seminar will take place on Tuesday, September 23, from 7:00 - 8.00 a.m. The session will be lead by Simon Authier of LAB Research as well as scientific leaders from AstraZeneca, GlaxoSmithKline and Johnson & Johnson. This seminar will provide the participants the opportunity to learn and evaluate the emerging trends in study design and their impact on different phases of drug development. This seminar draws on a broad range of global safety pharmacology experts who have introduced novel study designs and methodologies, which are important to the conduct of non-clinical safety pharmacology studies. Said Luc Mainville, president and CEO of LAB Research: “It is a seminar that supports new state-of-the-art research methods. LAB Research contributes to such advances with educational seminars such as this one as well as our continued support to the Safety Pharmacology Society.”

{embed=“includes/banner_ads” loc=“middle”}

Omnicare Clinical Researchopened an office in Sweden. “Omnicare Clinical Research continues to expand its worldwide presence through the opening of this new Swedish facility,” said Dale Evans, president and CEO. “We are committed to the Scandinavian marketplace, where we already have offices in Denmark and Finland. We’re looking forward to future growth and continued success with our partners in the region.”

Bioanalytical Systems announced its financial results for its third quarter and nine months of fiscal 2008, ending June 30, 2008. The company had previously announced the June 30, 2008, sale of its clinic in Baltimore, Maryland, and the resulting discontinuance of its Phase I clinical trials business. Michael Cox, CFO, stated, “With the strategic decision to sell our only Phase I clinic in June, we will be able to focus on continuing operations and to stress profitable operations. While the current quarter had a slight decrease in net income from continuing operations compared to a very strong quarter in the same period last year, our nine month results showed a 38% increase in pre-tax income from continuing operations compared to last year. We also increased our cash flow from continuing operations for the nine-month period from $3.4 million to $4.1 million. We are very encouraged by these results from our continuing operations,” he said. Here’s the release. 

{embed=“includes/banner_ads” loc=“third”}

Acurian announced that it has increased its investments in data modeling personnel and technology. It can now offer enhanced predictive and analytical services for patient recruitment. The company uses databases, real-time metrics, and performance-based contracts. Said Roger Smith, Acurian’s CIO and VP of operations: “The company’s enhanced modeling capabilities are not just internal business improvements. Too many sponsors are forced to rely on anecdotal or no data before, during and after a patient recruitment campaign. Our data experts and tools help sponsors better understand the enrollment continuum from response to randomization so that there are no surprises in time lines or budget allocations.”

Lux Biosciences announced the appointment of Paul Chaney to the company’s board of directors. Chaney is the former president of (OSI) Eyetech and executive vice president of OSI Pharmaceuticals. “Paul Chaney brings exceptional expertise in the global development and commercialization of ophthalmic pharmaceuticals at both large and small pharmaceutical companies,” said Ulrich Grau, Lux Biosciences president and CEO. “His counsel will be especially valuable to our company as we complete the clinical development of our first product and anticipate its commercialization in the United States and Europe in 2010.”

PSI has completed acquisition of Thywill,  a contract research organization (CRO) headquartered in Buenos Aires, Argentina, and managing clinical trials throughout Latin America. PSI handles clinical studies of all sizes and levels of complexity. PSI is a full-service CRO operating in Europe, Russia, North and South America. The addition of Argentina, Peru, Ecuador, Uruguay, Colombia, Chile and Mexico to PSI’s operational map enhances the company’s core strengths.

Have a news release? Send it to .